Landos Biopharma Publishes Results Of NX-13 Phase 1b Study In Ulcerative Colitis In Journal Of Crohn's And Colitis
Portfolio Pulse from Benzinga Newsdesk
Landos Biopharma has published the results of its NX-13 Phase 1b study in patients with ulcerative colitis in the Journal of Crohn's and Colitis. The study's findings are significant for the medical community and Landos Biopharma's development pipeline.
November 21, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The publication of NX-13 Phase 1b study results by Landos Biopharma in a reputable medical journal may positively influence investor perception and confidence in the company's research and development capabilities.
The publication of positive study results typically has a favorable impact on a biopharma company's stock price, as it reflects progress in the company's pipeline and increases the likelihood of successful drug development. Given that the results are published in a reputable journal, this adds credibility to the findings and may attract investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100